PMID- 22057509
OWN - NLM
STAT- MEDLINE
DCOM- 20120410
LR  - 20211021
IS  - 1865-3774 (Electronic)
IS  - 0925-5710 (Linking)
VI  - 94
IP  - 6
DP  - 2011 Dec
TI  - Successful treatment of lymphoid blastic crisis in chronic myelogenous leukemia 
      with the additional bcr/abl transcript using imatinib-combined chemotherapy and 
      high-dose chemotherapy with allogeneic bone marrow stem cell transplantation.
PG  - 561-6
LID - 10.1007/s12185-011-0956-y [doi]
AB  - Chronic myelogenous leukemia (CML) is a myeloproliferative disorder characterized 
      by the presence of the Philadelphia chromosome. Although the major BCR/ABL 
      transcript is present in majority of CML patients, the minor BCR/ABL transcript 
      is rarely reported as an additional chromosomal abnormality related to the 
      progression of CML. We describe the case of a 37-year-old woman who had CML and 
      pain in the extremities. She was diagnosed with lymphoid blast crisis of CML on 
      the basis of the following findings: presence of promyelocytes, myelocytes, and 
      metamyelocytes in peripheral blood smear; detection of major and minor BCR/ABL 
      transcripts by polymerase chain reaction analysis; proliferation of lymphoblastic 
      cells with abnormal B-cell phenotype; and aberrant expression of myeloid antigens 
      in the bone marrow. The patient underwent one course of idarubicin and cytosine 
      arabinose therapy combined with imatinib followed by 
      daunorubicin/cyclophosphamide plus vincristine and prednisone/L: -asparaginase 
      (DNR/COP/L: -ASP) therapy, high-dose cytosine arabinose, and CHOP therapy 
      (cyclophosphamide, doxorubicin, vincristine, and prednisolone). Subsequently, the 
      patient underwent high-dose chemotherapy (total body irradiation and 
      cyclophosphamide) followed by allogeneic bone marrow stem cell transplantation 
      from a human leukocyte antigen (HLA)-matched unrelated donor. After these 
      treatments, the patient was disease-free for 19 months. Our case suggests that 
      these treatments may be feasible, safe, and effective for the treatment of 
      patients with blast crisis CML expressing the minor BCR/ABL transcript.
FAU - Kawano, Noriaki
AU  - Kawano N
AD  - Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, 
      Miyazaki, Japan. kawanoriaki@yahoo.co.jp
FAU - Okuda, Shinya
AU  - Okuda S
FAU - Yoshida, Shuro
AU  - Yoshida S
FAU - Kugimiya, Hiroko
AU  - Kugimiya H
FAU - Ito, Masaki
AU  - Ito M
FAU - Horikawa, Nagako
AU  - Horikawa N
FAU - Chosa, Nobuaki
AU  - Chosa N
FAU - Hisakata, Tomoko
AU  - Hisakata T
FAU - Fukudome, Tomoko
AU  - Fukudome T
FAU - Sakurai, Ryoko
AU  - Sakurai R
FAU - Yamashita, Kiyoshi
AU  - Yamashita K
FAU - Ueda, Akira
AU  - Ueda A
FAU - Kanda, Yoshinobu
AU  - Kanda Y
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20111108
PL  - Japan
TA  - Int J Hematol
JT  - International journal of hematology
JID - 9111627
RN  - 0 (Benzamides)
RN  - 0 (Piperazines)
RN  - 0 (Pyrimidines)
RN  - 8A1O1M485B (Imatinib Mesylate)
RN  - EC 2.7.10.2 (Fusion Proteins, bcr-abl)
SB  - IM
MH  - Adult
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Benzamides
MH  - Blast Crisis/drug therapy/*therapy
MH  - Combined Modality Therapy
MH  - Female
MH  - Fusion Proteins, bcr-abl/genetics
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Imatinib Mesylate
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL 
      Positive/complications/*pathology/*therapy
MH  - Philadelphia Chromosome
MH  - Piperazines/administration & dosage
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/etiology/*pathology/*therapy
MH  - Pyrimidines/administration & dosage
MH  - Transplantation, Homologous
MH  - Treatment Outcome
EDAT- 2011/11/08 06:00
MHDA- 2012/04/11 06:00
CRDT- 2011/11/08 06:00
PHST- 2011/01/31 00:00 [received]
PHST- 2011/10/06 00:00 [accepted]
PHST- 2011/09/26 00:00 [revised]
PHST- 2011/11/08 06:00 [entrez]
PHST- 2011/11/08 06:00 [pubmed]
PHST- 2012/04/11 06:00 [medline]
AID - 10.1007/s12185-011-0956-y [doi]
PST - ppublish
SO  - Int J Hematol. 2011 Dec;94(6):561-6. doi: 10.1007/s12185-011-0956-y. Epub 2011 
      Nov 8.